header
  • home
  • contact us
  • timeline
  • news
  • editorials
  • slideshow
  • media
  • archives

Reasons For Hope (RFH)

is Search For A Cure's national HIV treatment news series.

RFH covers the latest in developing therapies for treating HIV/AIDS.

RFH is published in over 90 community newspapers and found on many websites for people infected or affected by HIV/AIDS. We encourage your comments and critiques. Email hope@sfac.org Feel free to copy and distribute any and all RFH articles.

Helpful Links

  • HIV legal issues
  • www.thebody.com
  • thebody.com Espanol
  • thebody.com Children
  • www.natap.org
  • AIDS medications
  • Medscape Drug Info
  • CDC Stats
  • CDC HIV Update
  • www.unaids.org/
  • www.clinicaltrials.gov
  • http://aidsmap.com/
  • Opportunities with AIDS/HIV

search our site

only search our site

Why We Should All be in a Clinical Trial

It is hard to get people to join a study of new medicines nowadays. This is mostly because people think the therapies we have are good enough. It's not true. HIV medicines fail some people. And they are too expensive for most of the world to use.

The medicines we have are not a cure, are a lifelong financial burden and have lots of side effects. The only way to see if new therapies work is to test them on people with HIV. The only way to see if a vaccine will work is to test it on people without HIV. If we want the day to come that HIV is a thing of the past the most important thing we can all do is find a study that needs us and join it.

archives: tastefully aged content

    Articles from the 14th CROI Conference on Retroviruses and Opportunistic Infections -- Los Angeles, California -- Feb 25-28, 2007

  • Metabolic Outcomes of ACTG 5142: A Prospective, randomized Phase III Trial of NRTI, PI, and NNRTI-sparing Regimens for Initial Treatment of HIV 03/05/07
  • Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r (Kaletra) + AZT/3TC Induction Followed by LPV/r Monotherapy- Compared with EFV +AZT/3TC (03/05/07)
  • Body Composition Changes in ARV-Naive Subjects Treated With Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 48-Week CT and DEXA Data 03/05/07
  • Entecavir HBV Therapy: does it have HIV activity? (03/05/07)
  • Insulin Resistance Predicts Rapid Response in People With HCV and HIV - written by Mark Mascolini (03/05/07)

  • CD4 Count Predicts Fatal Non-AIDS Cancers: Traditional Malignancies May also be AIDS-Related - Reported by David Alain Wohl (03/05/07)

  • Higher CD4 Count Prevents End-Organ Diseases (03/05/07)

  • HIV-Related Kidney Disease, ART Effects - written by Christina Wyatt (03/05/07)

  • Acute HIV infection: Transmitted Resistance in Newly Infected Patients - written by Charles Hicks, M.D. (03/05/07)

  • Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of Raltegravir (MK-0518), a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus (03/05/07) >

  • Motivate 1 Study: Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week Results of Phase 2b/3 Studies (03/05/07)

  • Increase in AIDS Cases (03/02/07)

  • Disparities in Life Expectancy Due to Suboptimal HIV Care in the US: Impact of Gender, Ethnicity and Race: (03/02/07)

  • Osteopenia in HIV: risk factors for screeing - written by Carl J. Fichtenbaum, M.D. (03/02/07)

  • Preclinical Data >From Two Novel NNRTI Idenix Compounds for the Treatment of HIV Presented at Conference on Retroviruses and Opportunistic Infections (CROI) (03/02/07)

  • Results from Two Phase III Studies on ISENTRESS (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) - Press Release (03/02/07) >

  • Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients - Press Release (03/02/07)

  • Metabolic and Cardiovacular Complications in HIV - written by Carl J. Fichtenbaum, M.D. (03/01/07)

  • Maraviroc Combined Analysis & MOTIVATE 2 (Europe, Australia, USA): 24 week Results (03/01/07)

  • Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy - written by Mark Mascolini (03/01/07)

  • TMC278 Matches Efavirenz in Treatment-Naive People - written by Mark Mascolini (03/01/07) >

  • Three new drugs promise options for HIV patients (03/01/07)

  • Lipodystrophy/Metabolic Complications of ART in South Africa (03/01/07)

  • Adverse Events/Complications of ART in Africa (03/01/07)

  • 48-week primary analysis of trial TMC278- C204: TMC278 demonstrates potent and sustained efficacy in ARV-naive patients (03/01/07)

  • The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients (03/01/07)

  • New HIV Drugs; Intl Drug Resistance (02/28/07)

  • Do Trace Levels of Resistance Affect Virologic Response? - written by Mark Mascolini (02/28/07)

  • Pfizer CCR5 Maraviroc 24 Weeks In Treatment-Experienced (02/28/07)

  • Lower CD4 Counts Boost Risk of "Non-AIDS" Cancers - written by Mark Mascolini (02/28/07)

  • People With HIV Infection Eat Too Much Saturated Fat - written by Mark Mascolini (02/28/07)

  • Integrase Inhibitor Adds More Punch to Salvage Regimens - written by Mark Mascolini (02/28/07)

  • Life Expectancy With HIV Still Low in High-Income Countries - written by Mark Mascolini (02/28/07)

  • CCR5 Blocker Looks Strong in Two International Salvage Trials - written by Mark Mascolini (02/28/07)

  • Nations Defend HIV Drugs With Tests for Hardy Strains (02/26/07)

  • Drug-resistant TB that kills HIV patients is spreading (02/26/07)

  • Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163 (02/26/07) >

  • Metabolic Outcomes of ACTG 5142: A Prospective, Randomized phase III trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial treatment of HIV-1 (02/26/07)

  • Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients (02/26/07)

  • Starting Antiretrovirals Later May Hurt Cognitive Function - written by Mark Mascolini (02/26/07)

  • Ezetimibe Reduces LDL-C for HIV+ on HAART (02/26/07)

  • How Antiretroviral Breaks May Raise Heart Disease Risk - written by Mark Mascolini (02/26/07)

  • CD4 Counts Predict Non-AIDS Disease Risk in FIRST Trial - written by Mark Mascolini (02/26/07)

  • Therapies for Improved Lipids, Belly Fat, and Limb Fat (02/26/07)


    October 2005:
    HAART, Heart Attacks & Fish Oil

    October 2005:
    CCR5 - A New Option For Those Who Have None Left

    July 2005:
    AIDS Experts Awaken to a False Alarm

    March 2005:
    Highlights From the 2005 Retrovirology Conference

    January 2005:
    Truvada

    2003:
    BU$HIT

    November 2003:
    Surfin' Made Easy

    May 2003:
    Once a Day

    May 2003:
    Terror

    May 2003:
    When All Else Fails:

    November 2002:
    Smart Sex

    November 2002:
    Unblocking the Clog

    September 2002:
    Unfit Mutants

    Spring 2002:
    Retro News

copyright Steven McGaughey 2006